Actuate Therapeutics, Inc. Common stock (ACTU) - Total Liabilities
Based on the latest financial reports, Actuate Therapeutics, Inc. Common stock (ACTU) has total liabilities worth $6.78 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Actuate Therapeutics, Inc. Common stock (ACTU) equity growth momentum to track the company's year-over-year net asset growth rate.
Actuate Therapeutics, Inc. Common stock - Total Liabilities Trend (2022–2024)
This chart illustrates how Actuate Therapeutics, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data.
Actuate Therapeutics, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of Actuate Therapeutics, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yanaprima Hastapersada Tbk
JK:YPAS
|
Indonesia | Rp142.38 Billion |
|
Xu Yuan Packaging Technology Co Ltd
TWO:8421
|
Taiwan | NT$1.15 Billion |
|
Gurktaler AG ST
VI:GAGS
|
Austria | €568.00K |
|
aap Implantate AG
F:AAQ1
|
Germany | €4.60 Million |
|
Eagle Veterinary Technology Co.Ltd
KQ:044960
|
Korea | ₩10.35 Billion |
|
Country Group Development Public Company Limited
BK:CGD
|
Thailand | ฿12.05 Billion |
|
Avecho Biotechnology Limited
F:OEZ
|
Germany | €5.55 Million |
|
The Steel Public Company Limited
BK:THE
|
Thailand | ฿1.80 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down Actuate Therapeutics, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACTU stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Actuate Therapeutics, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Actuate Therapeutics, Inc. Common stock (2022–2024)
The table below shows the annual total liabilities of Actuate Therapeutics, Inc. Common stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.21 Million | -91.02% |
| 2023-12-31 | $102.62 Million | +1716.08% |
| 2022-12-31 | $5.65 Million | -- |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more